Human Oncology & Pathogenesis Program

The Ingo Mellinghoff Lab

Memorial Sloan Kettering medical oncologist Ingo Mellinghoff

Ingo K. Mellinghoff, MD, FACP

Professor

Our laboratory focuses on the study of molecular pathways that regulate brain tumor growth. Our long-term goal is to develop therapeutic paradigms that target specific properties of primary brain tumors, including genetic alterations in cancer signaling pathways, unique aspects of brain tumor metabolism, or interactions of brain tumor cells with their brain microenvironment. Our studies in experimental brain tumor models are closely linked to the evaluation of novel agents in early-phase clinical trials.

Featured News

FDA Approves Drug for Low-Grade Glioma With IDH Gene Mutation

A new drug could be an effective treatment for some people with low-grade glioma.

Treatment for Low-Grade Glioma Advances to Phase 3 Clinical Trial

According to findings from a research team led by study first-author Ingo Mellinghoff, MD, Chair of MSK’s Department of Neurology: vorasidenib and ivosidenib reduced concentrations of 2-HG by more than 90%, were well-tolerated, and showed encouraging tumor responses amongst 49 patients enrolled in a multisite trial between April 2019 and April 2020. Vorasidenib showed greater brain penetration than ivosidenib. Based on the phase 1 trial results, vorasidenib was advanced to a phase 3 trial.

In the Clinic

Analyzing Spinal Fluid Could Guide Brain Tumor Diagnosis and Treatment

Cancer DNA taken from spinal fluid could serve as a liquid biopsy that provides information on brain tumor mutations.

View All Featured News

Publications Highlights

Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF; INDIGO Trial Investigators. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med. 2023 Aug 17;389(7):589-601. Epub 2023 Jun 4. PMID: 37272516. DOI: 10.1056/NEJMoa2304194.

Mellinghoff IK, Lu M, Wen PY, Taylor JW, Maher EA, Arrillaga-Romany I, Peters KB, Ellingson BM, Rosenblum MK, Chun S, Le K, Tassinari A, Choe S, Toubouti Y, Schoenfeld S, Pandya SS, Hassan I, Steelman L, Clarke JL, Cloughesy TF. Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. Nat Med. 2023 Mar;29(3):615-622. Epub 2023 Feb 23. PMID: 36823302. DOI: 10.1038/s41591-022-02141-2

Miller AM, Shah RH, Pentsova EI, Pourmaleki M, Briggs S, Distefano N, Zheng Y, Skakodub A, Mehta SA, Campos C, Hsieh WY, Selcuklu SD, Ling L, Meng F, Jing X, Samoila A, Bale TA, Tsui DWY, Grommes C, Viale A, Souweidane MM, Tabar V, Brennan CW, Reiner AS, Rosenblum M, Panageas KS, DeAngelis LM, Young RJ, Berger MF, Mellinghoff IK. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature. 2019 Jan; 565(7741):654-658. Epub 2019 Jan 23. PMID: 30675060. DOI: 10.1038/s41586-019-0882-3

Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, Codega P, Nichol D, Clark O, Hsieh WY, Rohle D, Rosenblum M, Viale A, Tabar VS, Brennan CW, Gavrilovic IT, Kaley TJ, Nolan CP, Omuro A, Pentsova E, Thomas AA, Tsyvkin E, Noy A, Palomba ML, Hamlin P, Sauter CS, Moskowitz CH, Wolfe J, Dogan A, Won M, Glass J, Peak S, Lallana EC, Hatzoglou V, Reiner AS, Gutin PH, Huse JT, Panageas KS, Graeber TG, Schultz N, DeAngelis LM, Mellinghoff IK. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discov. 2017 Sep;7(9):1018-1029. Epub 2017 Jun 15. PMID: 28619981. DOI: 10.1158/2159-8290.CD-17-0613.

Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, Kunii K, Pedraza A, Schalm S, Silverman L, Miller A, Wang F, Yang H, Chen Y, Kernytsky A, Rosenblum MK, Liu W, Biller SA, Su SM, Brennan CW, Chan TA, Graeber TG, Yen KE, Mellinghoff IK. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013 May 3;340(6132):626-30. Epub 2013 Apr 4. PMID: 23558169. DOI: 10.1126/science.1236062.

View All Publications

People

Ingo K. Mellinghoff, MD, FACP

Professor

Physician-scientist Ingo Mellinghoff studies signal transduction alterations in primary brain tumors.
MD, Technical University Munich (Germany)

646-888-2766: Office Phone
View physician profile: Physician profile

Members

Christian Grommes, MD — Christian Grommes
Associate Attending

Smrutiben Mehta
Senior Research Assistant

Arianna Izawa-Ishiguro
Pharmacology PhD Graduate Student

Annalisa V. Ferrotta

Graduate Student

Cinthia Garcia

Graduate Student

Meaghan Grogan

Research Technician

Bridget Holle

Research Technician

Shereeda Perez

Assistant to Chair

Timothy Pham

Research Technician

Lab Alumni

Daniel Navarrete
Senior Research Assistant

Brian Greenstein

Research Technician

Marlene Tartaro

Research Technician

Lab Affiliations

Achievements

Neuro-Oncology Scientific Award, American Academy of Neurology (2023)
Member, Association of American Physicians (2020)
Member, American Society of Clinical Investigation (2013)
Advanced Clinical Research Award, American Society of Clinical Oncology (2009)
Clinical Scientist Development Award, Doris Duke Charitable Foundation (2008)

Translational Science Award, Sidney Kimmel Foundation (2008)
Distinguished Scientist, Sontag Foundation (2007)
Scholar, Forbeck Research Foundation (2005)
Young Investigator Award, American Society of Clinical Oncology (2003)

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Career Opportunities

Apply now

Get in Touch

646-888-2766

Office Phone
646-888-2732

Office Fax
646-888-2784

Lab Phone

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Ingo K. Mellinghoff discloses the following relationships and financial interests:

Roche
Professional Services and Activities
Servier
Professional Services and Activities

Tango Therapeutics
Professional Services and Activities

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures